Oncology Leads Start-Up Biopharma Licensing In 2013
This article was originally published in Start Up
Executive Summary
In our annual review of start-up dealmaking, we find again that licensed cancer products represented the bulk of alliances. Nonprofits sourced many of these oncology assets.
You may also be interested in...
The Conundrum Of Alzheimer’s Disease R&D
Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.
Soriot’s Vision For AZ: A Focused Innovation-Driven Biopharma
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.
AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology
The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.